|This Slide: #32 of 100|
Slide #32. OPKO Health, Inc. — Inspiro Medical Ltd.
OPKO Health, Inc. (NASDAQ:OPK)
Inspiro Medical Ltd.
OPKO Health, Inc. (NYSE:OPK) has entered into a definitive agreement to acquire Inspiro Medical Ltd. ("Inspiro"), an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules to treat respiratory diseases. Inspiro's Inspiromatic is a "smart" easy-to-use dry powder inhaler with several advantages over existing devices.
Opko Health is a healthcare company. Co. manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, measures the blood plasma levels of prostate-derived kallikrein proteins and blood test results in point-of-care settings; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, Alpharen for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis, and VARUBI for prevention of chemotherapy-induced nausea and vomiting.
OPK SEC Filing Email Alerts Service
Open the OPK Page at The Online Investor »
Hold (2.50 out of 4)
(ranked lower than approx. 87% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite